Global GABA Receptor Agonists Market Growth 2026-2032

July 2026 | 224 pages | ID: GBCF0A91EE67EN
LP Information

Abstracts

The global GABA Receptor Agonists market size is predicted to grow from US$ 4549 million in 2025 to US$ 7654 million in 2032; it is expected to grow at a CAGR of 7.7% from 2026 to 2032.

GABA receptor agonists are prescription drugs and clinical formulations that target gamma-aminobutyric acid receptors in the central nervous system and either directly activate the receptors or, under a broader commercial market scope, enhance receptor-mediated inhibitory neurotransmission. They are not a single physical product form, but pharmaceutical products composed of active pharmaceutical ingredients, excipients, packaging materials, and delivery systems. Typical forms include white to off-white crystalline active ingredients, tablets, capsules, granules, oral suspensions, orally disintegrating tablets, injections, and lyophilized powders for injection. By receptor and pharmacological mechanism, they can be divided into GABA_A receptor-targeted drugs, GABA_B receptor-targeted drugs, partial agonists, positive allosteric modulators, and other GABAergic receptor-related drugs. Key technical requirements include stereochemical or polymorph control, impurity profiling, residual solvent control, immediate-release or sustained-release formulation design, aseptic filling, controlled-substance compliance, stability validation, and clinical therapeutic-window assessment. Their mechanism is to enhance inhibitory neurotransmission mediated by chloride channels or G-protein-coupled signaling, reduce neuronal excitability, and support treatment in spasticity, epilepsy, insomnia, procedural sedation and anesthesia, and selected rare neurological disorders.

Market development opportunities are mainly driven by long-term therapeutic demand in neurological and psychiatric disorders. Population aging, high prevalence of sleep disorders, a stable patient base in epilepsy and spasticity, increasing procedural sedation needs, and the approval of therapies for rare neurodevelopmental disorders are moving this category beyond mature low-priced generics toward specialty, pediatric, orphan-drug, and differentiated formulation markets. The strongest opportunities are expected in receptor subtype selectivity, partial agonism, short-acting and controllable pharmacology, lower residual sedation, reduced dependence potential, and dosage forms better suited for special populations.

The main market challenges are safety, abuse liability, and regulatory control. Traditional sedative-hypnotic and anxiolytic drugs are associated with somnolence, cognitive impairment, fall risk, respiratory depression, tolerance, physical dependence, and withdrawal or rebound effects. Several products are controlled substances, which raises compliance requirements for prescribing, manufacturing, distribution, and pharmacovigilance. Mature molecules face intense generic competition and persistent price erosion, while innovative drugs must prove clinical endpoints, long-term safety, reimbursement value, and differentiation against orexin receptor antagonists and newer non-GABA mechanisms in epilepsy and sleep medicine.

Downstream demand is shifting from broad sedation and empirical use toward more precise indication-based management. Hospitals increasingly value controllability, rapid onset and offset, and convenient administration in anesthesia, intensive care, epilepsy, and spasticity treatment. Retail and outpatient channels are focusing on standardized short-course use for insomnia and anxiety-related symptoms. Specialty demand is expanding into pediatric rare epilepsy, neurodevelopmental disorders, elderly patients, and patients with multiple comorbidities. Future growth is therefore unlikely to come from unrestricted prescription expansion; it will mainly come from safer products, clearer indications, better formulations, and substitution of older agents with improved therapeutic profiles.

LP Information, Inc. (LPI) ' newest research report, the ?GABA Receptor Agonists Industry Forecast? looks at past sales and reviews total world GABA Receptor Agonists sales in 2025, providing a comprehensive analysis by region and market sector of projected GABA Receptor Agonists sales for 2026 through 2032. With GABA Receptor Agonists sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world GABA Receptor Agonists industry.

This Insight Report provides a comprehensive analysis of the global GABA Receptor Agonists landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on GABA Receptor Agonists portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global GABA Receptor Agonists market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for GABA Receptor Agonists and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global GABA Receptor Agonists.

This report presents a comprehensive overview, market shares, and growth opportunities of GABA Receptor Agonists market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

• GABA_A receptor-targeted drugs
• GABA_B receptor-targeted drugs
• Others

Segmentation by Pharmacological Action Mode:

• Direct GABA receptor agonists
• Positive allosteric modulators
• Others

Segmentation by Dosage Form:

• Oral dosage forms
• Injectable dosage forms
• Others

Segmentation by Application:

• Attention Deficit Hyperactivity Disorder (ADHD)
• Psychiatric Disorders and Depression
• Alzheimer
• Epilepsy and Seizure
• Anxiety and Sleep Disorders
• Obesity and Alcoholism

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

• Sanofi
• Roche
• Novartis
• Viatris
• Teva Pharmaceutical Industries
• Sandoz
• Lundbeck
• Biocodex
• Immedica Pharma
• Azurity Pharmaceuticals
• Amneal Pharmaceuticals
• Fresenius Kabi
• Hikma Pharmaceuticals
• Eagle Pharmaceuticals
• PAION Pharma
• Mundipharma
• Eisai
• Sumitomo Pharma
• ANI Pharmaceuticals
• Zydus Lifesciences
• Aurobindo Pharma
• Sun Pharmaceutical Industries
• Cipla
• Torrent Pharmaceuticals
• Endo
• Baxter
• Hameln Pharma
• Ethypharm
• Neuraxpharm
• Sawai Pharmaceutical
• Towa Pharmaceutical
• Nichi-Iko Pharmaceutical
• Zhejiang Jingxin Pharmaceutical
• Jiangsu Nhwa Pharmaceutical
• Yichang Humanwell Pharmaceutical
• Shandong Sine Pharmaceutical
• Shanghai SPH Sine Pharmaceutical

Key Questions Addressed in this Report
What is the 10-year outlook for the global GABA Receptor Agonists market?
What factors are driving GABA Receptor Agonists market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do GABA Receptor Agonists market opportunities vary by end market size?
How does GABA Receptor Agonists break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global GABA Receptor Agonists Annual Sales 2021-2032
  2.1.2 World Current & Future Analysis for GABA Receptor Agonists by Geographic Region, 2021, 2025 & 2032
  2.1.3 World Current & Future Analysis for GABA Receptor Agonists by Country/Region, 2021, 2025 & 2032
2.2 GABA Receptor Agonists Segment by Type
  2.2.1 GABA_A receptor-targeted drugs
  2.2.2 GABA_B receptor-targeted drugs
  2.2.3 Others
  2.2.4 GABA Receptor Agonists Sales by Type
    2.2.4.1 Global GABA Receptor Agonists Sales Market Share by Type (2021-2026)
    2.2.4.2 Global GABA Receptor Agonists Revenue and Market Share by Type (2021-2026)
    2.2.4.3 Global GABA Receptor Agonists Sale Price by Type (2021-2026)
2.3 GABA Receptor Agonists Segment by Pharmacological Action Mode
  2.3.1 Direct GABA receptor agonists
  2.3.2 Positive allosteric modulators
  2.3.3 Others
  2.3.4 GABA Receptor Agonists Sales by Pharmacological Action Mode
    2.3.4.1 Global GABA Receptor Agonists Sales Market Share by Pharmacological Action Mode (2021-2026)
    2.3.4.2 Global GABA Receptor Agonists Revenue and Market Share by Pharmacological Action Mode (2021-2026)
    2.3.4.3 Global GABA Receptor Agonists Sale Price by Pharmacological Action Mode (2021-2026)
2.4 GABA Receptor Agonists Segment by Dosage Form
  2.4.1 Oral dosage forms
  2.4.2 Injectable dosage forms
  2.4.3 Others
  2.4.4 GABA Receptor Agonists Sales by Dosage Form
    2.4.4.1 Global GABA Receptor Agonists Sales Market Share by Dosage Form (2021-2026)
    2.4.4.2 Global GABA Receptor Agonists Revenue and Market Share by Dosage Form (2021-2026)
    2.4.4.3 Global GABA Receptor Agonists Sale Price by Dosage Form (2021-2026)
2.5 GABA Receptor Agonists Segment by Application
  2.5.1 Attention Deficit Hyperactivity Disorder (ADHD)
  2.5.2 Psychiatric Disorders and Depression
  2.5.3 Alzheimer
  2.5.4 Epilepsy and Seizure
  2.5.5 Anxiety and Sleep Disorders
  2.5.6 Obesity and Alcoholism
  2.5.7 GABA Receptor Agonists Sales by Application
    2.5.7.1 Global GABA Receptor Agonists Sale Market Share by Application (2021-2026)
    2.5.7.2 Global GABA Receptor Agonists Revenue and Market Share by Application (2021-2026)
    2.5.7.3 Global GABA Receptor Agonists Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global GABA Receptor Agonists Breakdown Data by Company
  3.1.1 Global GABA Receptor Agonists Annual Sales by Company (2021-2026)
  3.1.2 Global GABA Receptor Agonists Sales Market Share by Company (2021-2026)
3.2 Global GABA Receptor Agonists Annual Revenue by Company (2021-2026)
  3.2.1 Global GABA Receptor Agonists Revenue by Company (2021-2026)
  3.2.2 Global GABA Receptor Agonists Revenue Market Share by Company (2021-2026)
3.3 Global GABA Receptor Agonists Sale Price by Company
3.4 Key Manufacturers GABA Receptor Agonists Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers GABA Receptor Agonists Product Location Distribution
  3.4.2 Players GABA Receptor Agonists Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR GABA RECEPTOR AGONISTS BY GEOGRAPHIC REGION

4.1 World Historic GABA Receptor Agonists Market Size by Geographic Region (2021-2026)
  4.1.1 Global GABA Receptor Agonists Annual Sales by Geographic Region (2021-2026)
  4.1.2 Global GABA Receptor Agonists Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic GABA Receptor Agonists Market Size by Country/Region (2021-2026)
  4.2.1 Global GABA Receptor Agonists Annual Sales by Country/Region (2021-2026)
  4.2.2 Global GABA Receptor Agonists Annual Revenue by Country/Region (2021-2026)
4.3 Americas GABA Receptor Agonists Sales Growth
4.4 APAC GABA Receptor Agonists Sales Growth
4.5 Europe GABA Receptor Agonists Sales Growth
4.6 Middle East & Africa GABA Receptor Agonists Sales Growth

5 AMERICAS

5.1 Americas GABA Receptor Agonists Sales by Country
  5.1.1 Americas GABA Receptor Agonists Sales by Country (2021-2026)
  5.1.2 Americas GABA Receptor Agonists Revenue by Country (2021-2026)
5.2 Americas GABA Receptor Agonists Sales by Type (2021-2026)
5.3 Americas GABA Receptor Agonists Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC GABA Receptor Agonists Sales by Region
  6.1.1 APAC GABA Receptor Agonists Sales by Region (2021-2026)
  6.1.2 APAC GABA Receptor Agonists Revenue by Region (2021-2026)
6.2 APAC GABA Receptor Agonists Sales by Type (2021-2026)
6.3 APAC GABA Receptor Agonists Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe GABA Receptor Agonists by Country
  7.1.1 Europe GABA Receptor Agonists Sales by Country (2021-2026)
  7.1.2 Europe GABA Receptor Agonists Revenue by Country (2021-2026)
7.2 Europe GABA Receptor Agonists Sales by Type (2021-2026)
7.3 Europe GABA Receptor Agonists Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa GABA Receptor Agonists by Country
  8.1.1 Middle East & Africa GABA Receptor Agonists Sales by Country (2021-2026)
  8.1.2 Middle East & Africa GABA Receptor Agonists Revenue by Country (2021-2026)
8.2 Middle East & Africa GABA Receptor Agonists Sales by Type (2021-2026)
8.3 Middle East & Africa GABA Receptor Agonists Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of GABA Receptor Agonists
10.3 Manufacturing Process Analysis of GABA Receptor Agonists
10.4 Industry Chain Structure of GABA Receptor Agonists

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 GABA Receptor Agonists Distributors
11.3 GABA Receptor Agonists Customer

12 WORLD FORECAST REVIEW FOR GABA RECEPTOR AGONISTS BY GEOGRAPHIC REGION

12.1 Global GABA Receptor Agonists Market Size Forecast by Region
  12.1.1 Global GABA Receptor Agonists Forecast by Region (2027-2032)
  12.1.2 Global GABA Receptor Agonists Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global GABA Receptor Agonists Forecast by Type (2027-2032)
12.7 Global GABA Receptor Agonists Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 Sanofi
  13.1.1 Sanofi Company Information
  13.1.2 Sanofi GABA Receptor Agonists Product Portfolios and Specifications
  13.1.3 Sanofi GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  13.1.4 Sanofi Main Business Overview
  13.1.5 Sanofi Latest Developments
13.2 Roche
  13.2.1 Roche Company Information
  13.2.2 Roche GABA Receptor Agonists Product Portfolios and Specifications
  13.2.3 Roche GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  13.2.4 Roche Main Business Overview
  13.2.5 Roche Latest Developments
13.3 Novartis
  13.3.1 Novartis Company Information
  13.3.2 Novartis GABA Receptor Agonists Product Portfolios and Specifications
  13.3.3 Novartis GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  13.3.4 Novartis Main Business Overview
  13.3.5 Novartis Latest Developments
13.4 Viatris
  13.4.1 Viatris Company Information
  13.4.2 Viatris GABA Receptor Agonists Product Portfolios and Specifications
  13.4.3 Viatris GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  13.4.4 Viatris Main Business Overview
  13.4.5 Viatris Latest Developments
13.5 Teva Pharmaceutical Industries
  13.5.1 Teva Pharmaceutical Industries Company Information
  13.5.2 Teva Pharmaceutical Industries GABA Receptor Agonists Product Portfolios and Specifications
  13.5.3 Teva Pharmaceutical Industries GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  13.5.4 Teva Pharmaceutical Industries Main Business Overview
  13.5.5 Teva Pharmaceutical Industries Latest Developments
13.6 Sandoz
  13.6.1 Sandoz Company Information
  13.6.2 Sandoz GABA Receptor Agonists Product Portfolios and Specifications
  13.6.3 Sandoz GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  13.6.4 Sandoz Main Business Overview
  13.6.5 Sandoz Latest Developments
13.7 Lundbeck
  13.7.1 Lundbeck Company Information
  13.7.2 Lundbeck GABA Receptor Agonists Product Portfolios and Specifications
  13.7.3 Lundbeck GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  13.7.4 Lundbeck Main Business Overview
  13.7.5 Lundbeck Latest Developments
13.8 Biocodex
  13.8.1 Biocodex Company Information
  13.8.2 Biocodex GABA Receptor Agonists Product Portfolios and Specifications
  13.8.3 Biocodex GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  13.8.4 Biocodex Main Business Overview
  13.8.5 Biocodex Latest Developments
13.9 Immedica Pharma
  13.9.1 Immedica Pharma Company Information
  13.9.2 Immedica Pharma GABA Receptor Agonists Product Portfolios and Specifications
  13.9.3 Immedica Pharma GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  13.9.4 Immedica Pharma Main Business Overview
  13.9.5 Immedica Pharma Latest Developments
13.10 Azurity Pharmaceuticals
  13.10.1 Azurity Pharmaceuticals Company Information
  13.10.2 Azurity Pharmaceuticals GABA Receptor Agonists Product Portfolios and Specifications
  13.10.3 Azurity Pharmaceuticals GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  13.10.4 Azurity Pharmaceuticals Main Business Overview
  13.10.5 Azurity Pharmaceuticals Latest Developments
13.11 Amneal Pharmaceuticals
  13.11.1 Amneal Pharmaceuticals Company Information
  13.11.2 Amneal Pharmaceuticals GABA Receptor Agonists Product Portfolios and Specifications
  13.11.3 Amneal Pharmaceuticals GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  13.11.4 Amneal Pharmaceuticals Main Business Overview
  13.11.5 Amneal Pharmaceuticals Latest Developments
13.12 Fresenius Kabi
  13.12.1 Fresenius Kabi Company Information
  13.12.2 Fresenius Kabi GABA Receptor Agonists Product Portfolios and Specifications
  13.12.3 Fresenius Kabi GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  13.12.4 Fresenius Kabi Main Business Overview
  13.12.5 Fresenius Kabi Latest Developments
13.13 Hikma Pharmaceuticals
  13.13.1 Hikma Pharmaceuticals Company Information
  13.13.2 Hikma Pharmaceuticals GABA Receptor Agonists Product Portfolios and Specifications
  13.13.3 Hikma Pharmaceuticals GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  13.13.4 Hikma Pharmaceuticals Main Business Overview
  13.13.5 Hikma Pharmaceuticals Latest Developments
13.14 Eagle Pharmaceuticals
  13.14.1 Eagle Pharmaceuticals Company Information
  13.14.2 Eagle Pharmaceuticals GABA Receptor Agonists Product Portfolios and Specifications
  13.14.3 Eagle Pharmaceuticals GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  13.14.4 Eagle Pharmaceuticals Main Business Overview
  13.14.5 Eagle Pharmaceuticals Latest Developments
13.15 PAION Pharma
  13.15.1 PAION Pharma Company Information
  13.15.2 PAION Pharma GABA Receptor Agonists Product Portfolios and Specifications
  13.15.3 PAION Pharma GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  13.15.4 PAION Pharma Main Business Overview
  13.15.5 PAION Pharma Latest Developments
13.16 Mundipharma
  13.16.1 Mundipharma Company Information
  13.16.2 Mundipharma GABA Receptor Agonists Product Portfolios and Specifications
  13.16.3 Mundipharma GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  13.16.4 Mundipharma Main Business Overview
  13.16.5 Mundipharma Latest Developments
13.17 Eisai
  13.17.1 Eisai Company Information
  13.17.2 Eisai GABA Receptor Agonists Product Portfolios and Specifications
  13.17.3 Eisai GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  13.17.4 Eisai Main Business Overview
  13.17.5 Eisai Latest Developments
13.18 Sumitomo Pharma
  13.18.1 Sumitomo Pharma Company Information
  13.18.2 Sumitomo Pharma GABA Receptor Agonists Product Portfolios and Specifications
  13.18.3 Sumitomo Pharma GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  13.18.4 Sumitomo Pharma Main Business Overview
  13.18.5 Sumitomo Pharma Latest Developments
13.19 ANI Pharmaceuticals
  13.19.1 ANI Pharmaceuticals Company Information
  13.19.2 ANI Pharmaceuticals GABA Receptor Agonists Product Portfolios and Specifications
  13.19.3 ANI Pharmaceuticals GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  13.19.4 ANI Pharmaceuticals Main Business Overview
  13.19.5 ANI Pharmaceuticals Latest Developments
13.20 Zydus Lifesciences
  13.20.1 Zydus Lifesciences Company Information
  13.20.2 Zydus Lifesciences GABA Receptor Agonists Product Portfolios and Specifications
  13.20.3 Zydus Lifesciences GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  13.20.4 Zydus Lifesciences Main Business Overview
  13.20.5 Zydus Lifesciences Latest Developments
13.21 Aurobindo Pharma
  13.21.1 Aurobindo Pharma Company Information
  13.21.2 Aurobindo Pharma GABA Receptor Agonists Product Portfolios and Specifications
  13.21.3 Aurobindo Pharma GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  13.21.4 Aurobindo Pharma Main Business Overview
  13.21.5 Aurobindo Pharma Latest Developments
13.22 Sun Pharmaceutical Industries
  13.22.1 Sun Pharmaceutical Industries Company Information
  13.22.2 Sun Pharmaceutical Industries GABA Receptor Agonists Product Portfolios and Specifications
  13.22.3 Sun Pharmaceutical Industries GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  13.22.4 Sun Pharmaceutical Industries Main Business Overview
  13.22.5 Sun Pharmaceutical Industries Latest Developments
13.23 Cipla
  13.23.1 Cipla Company Information
  13.23.2 Cipla GABA Receptor Agonists Product Portfolios and Specifications
  13.23.3 Cipla GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  13.23.4 Cipla Main Business Overview
  13.23.5 Cipla Latest Developments
13.24 Torrent Pharmaceuticals
  13.24.1 Torrent Pharmaceuticals Company Information
  13.24.2 Torrent Pharmaceuticals GABA Receptor Agonists Product Portfolios and Specifications
  13.24.3 Torrent Pharmaceuticals GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  13.24.4 Torrent Pharmaceuticals Main Business Overview
  13.24.5 Torrent Pharmaceuticals Latest Developments
13.25 Endo
  13.25.1 Endo Company Information
  13.25.2 Endo GABA Receptor Agonists Product Portfolios and Specifications
  13.25.3 Endo GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  13.25.4 Endo Main Business Overview
  13.25.5 Endo Latest Developments
13.26 Baxter
  13.26.1 Baxter Company Information
  13.26.2 Baxter GABA Receptor Agonists Product Portfolios and Specifications
  13.26.3 Baxter GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  13.26.4 Baxter Main Business Overview
  13.26.5 Baxter Latest Developments
13.27 Hameln Pharma
  13.27.1 Hameln Pharma Company Information
  13.27.2 Hameln Pharma GABA Receptor Agonists Product Portfolios and Specifications
  13.27.3 Hameln Pharma GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  13.27.4 Hameln Pharma Main Business Overview
  13.27.5 Hameln Pharma Latest Developments
13.28 Ethypharm
  13.28.1 Ethypharm Company Information
  13.28.2 Ethypharm GABA Receptor Agonists Product Portfolios and Specifications
  13.28.3 Ethypharm GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  13.28.4 Ethypharm Main Business Overview
  13.28.5 Ethypharm Latest Developments
13.29 Neuraxpharm
  13.29.1 Neuraxpharm Company Information
  13.29.2 Neuraxpharm GABA Receptor Agonists Product Portfolios and Specifications
  13.29.3 Neuraxpharm GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  13.29.4 Neuraxpharm Main Business Overview
  13.29.5 Neuraxpharm Latest Developments
13.30 Sawai Pharmaceutical
  13.30.1 Sawai Pharmaceutical Company Information
  13.30.2 Sawai Pharmaceutical GABA Receptor Agonists Product Portfolios and Specifications
  13.30.3 Sawai Pharmaceutical GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  13.30.4 Sawai Pharmaceutical Main Business Overview
  13.30.5 Sawai Pharmaceutical Latest Developments
13.31 Towa Pharmaceutical
  13.31.1 Towa Pharmaceutical Company Information
  13.31.2 Towa Pharmaceutical GABA Receptor Agonists Product Portfolios and Specifications
  13.31.3 Towa Pharmaceutical GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  13.31.4 Towa Pharmaceutical Main Business Overview
  13.31.5 Towa Pharmaceutical Latest Developments
13.32 Nichi-Iko Pharmaceutical
  13.32.1 Nichi-Iko Pharmaceutical Company Information
  13.32.2 Nichi-Iko Pharmaceutical GABA Receptor Agonists Product Portfolios and Specifications
  13.32.3 Nichi-Iko Pharmaceutical GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  13.32.4 Nichi-Iko Pharmaceutical Main Business Overview
  13.32.5 Nichi-Iko Pharmaceutical Latest Developments
13.33 Zhejiang Jingxin Pharmaceutical
  13.33.1 Zhejiang Jingxin Pharmaceutical Company Information
  13.33.2 Zhejiang Jingxin Pharmaceutical GABA Receptor Agonists Product Portfolios and Specifications
  13.33.3 Zhejiang Jingxin Pharmaceutical GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  13.33.4 Zhejiang Jingxin Pharmaceutical Main Business Overview
  13.33.5 Zhejiang Jingxin Pharmaceutical Latest Developments
13.34 Jiangsu Nhwa Pharmaceutical
  13.34.1 Jiangsu Nhwa Pharmaceutical Company Information
  13.34.2 Jiangsu Nhwa Pharmaceutical GABA Receptor Agonists Product Portfolios and Specifications
  13.34.3 Jiangsu Nhwa Pharmaceutical GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  13.34.4 Jiangsu Nhwa Pharmaceutical Main Business Overview
  13.34.5 Jiangsu Nhwa Pharmaceutical Latest Developments
13.35 Yichang Humanwell Pharmaceutical
  13.35.1 Yichang Humanwell Pharmaceutical Company Information
  13.35.2 Yichang Humanwell Pharmaceutical GABA Receptor Agonists Product Portfolios and Specifications
  13.35.3 Yichang Humanwell Pharmaceutical GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  13.35.4 Yichang Humanwell Pharmaceutical Main Business Overview
  13.35.5 Yichang Humanwell Pharmaceutical Latest Developments
13.36 Shandong Sine Pharmaceutical
  13.36.1 Shandong Sine Pharmaceutical Company Information
  13.36.2 Shandong Sine Pharmaceutical GABA Receptor Agonists Product Portfolios and Specifications
  13.36.3 Shandong Sine Pharmaceutical GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  13.36.4 Shandong Sine Pharmaceutical Main Business Overview
  13.36.5 Shandong Sine Pharmaceutical Latest Developments
13.37 Shanghai SPH Sine Pharmaceutical
  13.37.1 Shanghai SPH Sine Pharmaceutical Company Information
  13.37.2 Shanghai SPH Sine Pharmaceutical GABA Receptor Agonists Product Portfolios and Specifications
  13.37.3 Shanghai SPH Sine Pharmaceutical GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  13.37.4 Shanghai SPH Sine Pharmaceutical Main Business Overview
  13.37.5 Shanghai SPH Sine Pharmaceutical Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. GABA Receptor Agonists Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. GABA Receptor Agonists Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of GABA_A receptor-targeted drugs
Table 4. Major Players of GABA_B receptor-targeted drugs
Table 5. Major Players of Others
Table 6. Global GABA Receptor Agonists Sales by Type (2021-2026) & (K Dose)
Table 7. Global GABA Receptor Agonists Sales Market Share by Type (2021-2026)
Table 8. Global GABA Receptor Agonists Revenue by Type (2021-2026) & ($ million)
Table 9. Global GABA Receptor Agonists Revenue Market Share by Type (2021-2026)
Table 10. Global GABA Receptor Agonists Sale Price by Type (2021-2026) & (USD/Pcs)
Table 11. Major Players of Direct GABA receptor agonists
Table 12. Major Players of Positive allosteric modulators
Table 13. Major Players of Others
Table 14. Global GABA Receptor Agonists Sales by Pharmacological Action Mode (2021-2026) & (K Dose)
Table 15. Global GABA Receptor Agonists Sales Market Share by Pharmacological Action Mode (2021-2026)
Table 16. Global GABA Receptor Agonists Revenue by Pharmacological Action Mode (2021-2026) & ($ million)
Table 17. Global GABA Receptor Agonists Revenue Market Share by Pharmacological Action Mode (2021-2026)
Table 18. Global GABA Receptor Agonists Sale Price by Pharmacological Action Mode (2021-2026) & (USD/Pcs)
Table 19. Major Players of Oral dosage forms
Table 20. Major Players of Injectable dosage forms
Table 21. Major Players of Others
Table 22. Global GABA Receptor Agonists Sales by Dosage Form (2021-2026) & (K Dose)
Table 23. Global GABA Receptor Agonists Sales Market Share by Dosage Form (2021-2026)
Table 24. Global GABA Receptor Agonists Revenue by Dosage Form (2021-2026) & ($ million)
Table 25. Global GABA Receptor Agonists Revenue Market Share by Dosage Form (2021-2026)
Table 26. Global GABA Receptor Agonists Sale Price by Dosage Form (2021-2026) & (USD/Pcs)
Table 27. Global GABA Receptor Agonists Sale by Application (2021-2026) & (K Dose)
Table 28. Global GABA Receptor Agonists Sale Market Share by Application (2021-2026)
Table 29. Global GABA Receptor Agonists Revenue by Application (2021-2026) & ($ million)
Table 30. Global GABA Receptor Agonists Revenue Market Share by Application (2021-2026)
Table 31. Global GABA Receptor Agonists Sale Price by Application (2021-2026) & (USD/Pcs)
Table 32. Global GABA Receptor Agonists Sales by Company (2021-2026) & (K Dose)
Table 33. Global GABA Receptor Agonists Sales Market Share by Company (2021-2026)
Table 34. Global GABA Receptor Agonists Revenue by Company (2021-2026) & ($ millions)
Table 35. Global GABA Receptor Agonists Revenue Market Share by Company (2021-2026)
Table 36. Global GABA Receptor Agonists Sale Price by Company (2021-2026) & (USD/Pcs)
Table 37. Key Manufacturers GABA Receptor Agonists Producing Area Distribution and Sales Area
Table 38. Players GABA Receptor Agonists Products Offered
Table 39. GABA Receptor Agonists Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 40. New Products and Potential Entrants
Table 41. Market M&A Activity & Strategy
Table 42. Global GABA Receptor Agonists Sales by Geographic Region (2021-2026) & (K Dose)
Table 43. Global GABA Receptor Agonists Sales Market Share Geographic Region (2021-2026)
Table 44. Global GABA Receptor Agonists Revenue by Geographic Region (2021-2026) & ($ millions)
Table 45. Global GABA Receptor Agonists Revenue Market Share by Geographic Region (2021-2026)
Table 46. Global GABA Receptor Agonists Sales by Country/Region (2021-2026) & (K Dose)
Table 47. Global GABA Receptor Agonists Sales Market Share by Country/Region (2021-2026)
Table 48. Global GABA Receptor Agonists Revenue by Country/Region (2021-2026) & ($ millions)
Table 49. Global GABA Receptor Agonists Revenue Market Share by Country/Region (2021-2026)
Table 50. Americas GABA Receptor Agonists Sales by Country (2021-2026) & (K Dose)
Table 51. Americas GABA Receptor Agonists Sales Market Share by Country (2021-2026)
Table 52. Americas GABA Receptor Agonists Revenue by Country (2021-2026) & ($ millions)
Table 53. Americas GABA Receptor Agonists Sales by Type (2021-2026) & (K Dose)
Table 54. Americas GABA Receptor Agonists Sales by Application (2021-2026) & (K Dose)
Table 55. APAC GABA Receptor Agonists Sales by Region (2021-2026) & (K Dose)
Table 56. APAC GABA Receptor Agonists Sales Market Share by Region (2021-2026)
Table 57. APAC GABA Receptor Agonists Revenue by Region (2021-2026) & ($ millions)
Table 58. APAC GABA Receptor Agonists Sales by Type (2021-2026) & (K Dose)
Table 59. APAC GABA Receptor Agonists Sales by Application (2021-2026) & (K Dose)
Table 60. Europe GABA Receptor Agonists Sales by Country (2021-2026) & (K Dose)
Table 61. Europe GABA Receptor Agonists Revenue by Country (2021-2026) & ($ millions)
Table 62. Europe GABA Receptor Agonists Sales by Type (2021-2026) & (K Dose)
Table 63. Europe GABA Receptor Agonists Sales by Application (2021-2026) & (K Dose)
Table 64. Middle East & Africa GABA Receptor Agonists Sales by Country (2021-2026) & (K Dose)
Table 65. Middle East & Africa GABA Receptor Agonists Revenue Market Share by Country (2021-2026)
Table 66. Middle East & Africa GABA Receptor Agonists Sales by Type (2021-2026) & (K Dose)
Table 67. Middle East & Africa GABA Receptor Agonists Sales by Application (2021-2026) & (K Dose)
Table 68. Key Market Drivers & Growth Opportunities of GABA Receptor Agonists
Table 69. Key Market Challenges & Risks of GABA Receptor Agonists
Table 70. Key Industry Trends of GABA Receptor Agonists
Table 71. GABA Receptor Agonists Raw Material
Table 72. Key Suppliers of Raw Materials
Table 73. GABA Receptor Agonists Distributors List
Table 74. GABA Receptor Agonists Customer List
Table 75. Global GABA Receptor Agonists Sales Forecast by Region (2027-2032) & (K Dose)
Table 76. Global GABA Receptor Agonists Revenue Forecast by Region (2027-2032) & ($ millions)
Table 77. Americas GABA Receptor Agonists Sales Forecast by Country (2027-2032) & (K Dose)
Table 78. Americas GABA Receptor Agonists Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 79. APAC GABA Receptor Agonists Sales Forecast by Region (2027-2032) & (K Dose)
Table 80. APAC GABA Receptor Agonists Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 81. Europe GABA Receptor Agonists Sales Forecast by Country (2027-2032) & (K Dose)
Table 82. Europe GABA Receptor Agonists Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. Middle East & Africa GABA Receptor Agonists Sales Forecast by Country (2027-2032) & (K Dose)
Table 84. Middle East & Africa GABA Receptor Agonists Revenue Forecast by Country (2027-2032) & ($ millions)
Table 85. Global GABA Receptor Agonists Sales Forecast by Type (2027-2032) & (K Dose)
Table 86. Global GABA Receptor Agonists Revenue Forecast by Type (2027-2032) & ($ millions)
Table 87. Global GABA Receptor Agonists Sales Forecast by Application (2027-2032) & (K Dose)
Table 88. Global GABA Receptor Agonists Revenue Forecast by Application (2027-2032) & ($ millions)
Table 89. Sanofi Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors
Table 90. Sanofi GABA Receptor Agonists Product Portfolios and Specifications
Table 91. Sanofi GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026)
Table 92. Sanofi Main Business
Table 93. Sanofi Latest Developments
Table 94. Roche Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors
Table 95. Roche GABA Receptor Agonists Product Portfolios and Specifications
Table 96. Roche GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026)
Table 97. Roche Main Business
Table 98. Roche Latest Developments
Table 99. Novartis Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors
Table 100. Novartis GABA Receptor Agonists Product Portfolios and Specifications
Table 101. Novartis GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026)
Table 102. Novartis Main Business
Table 103. Novartis Latest Developments
Table 104. Viatris Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors
Table 105. Viatris GABA Receptor Agonists Product Portfolios and Specifications
Table 106. Viatris GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026)
Table 107. Viatris Main Business
Table 108. Viatris Latest Developments
Table 109. Teva Pharmaceutical Industries Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors
Table 110. Teva Pharmaceutical Industries GABA Receptor Agonists Product Portfolios and Specifications
Table 111. Teva Pharmaceutical Industries GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026)
Table 112. Teva Pharmaceutical Industries Main Business
Table 113. Teva Pharmaceutical Industries Latest Developments
Table 114. Sandoz Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors
Table 115. Sandoz GABA Receptor Agonists Product Portfolios and Specifications
Table 116. Sandoz GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026)
Table 117. Sandoz Main Business
Table 118. Sandoz Latest Developments
Table 119. Lundbeck Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors
Table 120. Lundbeck GABA Receptor Agonists Product Portfolios and Specifications
Table 121. Lundbeck GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026)
Table 122. Lundbeck Main Business
Table 123. Lundbeck Latest Developments
Table 124. Biocodex Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors
Table 125. Biocodex GABA Receptor Agonists Product Portfolios and Specifications
Table 126. Biocodex GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026)
Table 127. Biocodex Main Business
Table 128. Biocodex Latest Developments
Table 129. Immedica Pharma Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors
Table 130. Immedica Pharma GABA Receptor Agonists Product Portfolios and Specifications
Table 131. Immedica Pharma GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026)
Table 132. Immedica Pharma Main Business
Table 133. Immedica Pharma Latest Developments
Table 134. Azurity Pharmaceuticals Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors
Table 135. Azurity Pharmaceuticals GABA Receptor Agonists Product Portfolios and Specifications
Table 136. Azurity Pharmaceuticals GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026)
Table 137. Azurity Pharmaceuticals Main Business
Table 138. Azurity Pharmaceuticals Latest Developments
Table 139. Amneal Pharmaceuticals Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors
Table 140. Amneal Pharmaceuticals GABA Receptor Agonists Product Portfolios and Specifications
Table 141. Amneal Pharmaceuticals GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026)
Table 142. Amneal Pharmaceuticals Main Business
Table 143. Amneal Pharmaceuticals Latest Developments
Table 144. Fresenius Kabi Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors
Table 145. Fresenius Kabi GABA Receptor Agonists Product Portfolios and Specifications
Table 146. Fresenius Kabi GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026)
Table 147. Fresenius Kabi Main Business
Table 148. Fresenius Kabi Latest Developments
Table 149. Hikma Pharmaceuticals Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors
Table 150. Hikma Pharmaceuticals GABA Receptor Agonists Product Portfolios and Specifications
Table 151. Hikma Pharmaceuticals GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026)
Table 152. Hikma Pharmaceuticals Main Business
Table 153. Hikma Pharmaceuticals Latest Developments
Table 154. Eagle Pharmaceuticals Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors
Table 155. Eagle Pharmaceuticals GABA Receptor Agonists Product Portfolios and Specifications
Table 156. Eagle Pharmaceuticals GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026)
Table 157. Eagle Pharmaceuticals Main Business
Table 158. Eagle Pharmaceuticals Latest Developments
Table 159. PAION Pharma Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors
Table 160. PAION Pharma GABA Receptor Agonists Product Portfolios and Specifications
Table 161. PAION Pharma GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026)
Table 162. PAION Pharma Main Business
Table 163. PAION Pharma Latest Developments
Table 164. Mundipharma Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors
Table 165. Mundipharma GABA Receptor Agonists Product Portfolios and Specifications
Table 166. Mundipharma GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026)
Table 167. Mundipharma Main Business
Table 168. Mundipharma Latest Developments
Table 169. Eisai Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors
Table 170. Eisai GABA Receptor Agonists Product Portfolios and Specifications
Table 171. Eisai GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026)
Table 172. Eisai Main Business
Table 173. Eisai Latest Developments
Table 174. Sumitomo Pharma Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors
Table 175. Sumitomo Pharma GABA Receptor Agonists Product Portfolios and Specifications
Table 176. Sumitomo Pharma GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026)
Table 177. Sumitomo Pharma Main Business
Table 178. Sumitomo Pharma Latest Developments
Table 179. ANI Pharmaceuticals Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors
Table 180. ANI Pharmaceuticals GABA Receptor Agonists Product Portfolios and Specifications
Table 181. ANI Pharmaceuticals GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026)
Table 182. ANI Pharmaceuticals Main Business
Table 183. ANI Pharmaceuticals Latest Developments
Table 184. Zydus Lifesciences Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors
Table 185. Zydus Lifesciences GABA Receptor Agonists Product Portfolios and Specifications
Table 186. Zydus Lifesciences GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026)
Table 187. Zydus Lifesciences Main Business
Table 188. Zydus Lifesciences Latest Developments
Table 189. Aurobindo Pharma Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors
Table 190. Aurobindo Pharma GABA Receptor Agonists Product Portfolios and Specifications
Table 191. Aurobindo Pharma GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026)
Table 192. Aurobindo Pharma Main Business
Table 193. Aurobindo Pharma Latest Developments
Table 194. Sun Pharmaceutical Industries Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors
Table 195. Sun Pharmaceutical Industries GABA Receptor Agonists Product Portfolios and Specifications
Table 196. Sun Pharmaceutical Industries GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026)
Table 197. Sun Pharmaceutical Industries Main Business
Table 198. Sun Pharmaceutical Industries Latest Developments
Table 199. Cipla Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors
Table 200. Cipla GABA Receptor Agonists Product Portfolios and Specifications
Table 201. Cipla GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026)
Table 202. Cipla Main Business
Table 203. Cipla Latest Developments
Table 204. Torrent Pharmaceuticals Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors
Table 205. Torrent Pharmaceuticals GABA Receptor Agonists Product Portfolios and Specifications
Table 206. Torrent Pharmaceuticals GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026)
Table 207. Torrent Pharmaceuticals Main Business
Table 208. Torrent Pharmaceuticals Latest Developments
Table 209. Endo Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors
Table 210. Endo GABA Receptor Agonists Product Portfolios and Specifications
Table 211. Endo GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026)
Table 212. Endo Main Business
Table 213. Endo Latest Developments
Table 214. Baxter Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors
Table 215. Baxter GABA Receptor Agonists Product Portfolios and Specifications
Table 216. Baxter GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026)
Table 217. Baxter Main Business
Table 218. Baxter Latest Developments
Table 219. Hameln Pharma Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors
Table 220. Hameln Pharma GABA Receptor Agonists Product Portfolios and Specifications
Table 221. Hameln Pharma GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026)
Table 222. Hameln Pharma Main Business
Table 223. Hameln Pharma Latest Developments
Table 224. Ethypharm Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors
Table 225. Ethypharm GABA Receptor Agonists Product Portfolios and Specifications
Table 226. Ethypharm GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026)
Table 227. Ethypharm Main Business
Table 228. Ethypharm Latest Developments
Table 229. Neuraxpharm Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors
Table 230. Neuraxpharm GABA Receptor Agonists Product Portfolios and Specifications
Table 231. Neuraxpharm GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026)
Table 232. Neuraxpharm Main Business
Table 233. Neuraxpharm Latest Developments
Table 234. Sawai Pharmaceutical Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors
Table 235. Sawai Pharmaceutical GABA Receptor Agonists Product Portfolios and Specifications
Table 236. Sawai Pharmaceutical GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026)
Table 237. Sawai Pharmaceutical Main Business
Table 238. Sawai Pharmaceutical Latest Developments
Table 239. Towa Pharmaceutical Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors
Table 240. Towa Pharmaceutical GABA Receptor Agonists Product Portfolios and Specifications
Table 241. Towa Pharmaceutical GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026)
Table 242. Towa Pharmaceutical Main Business
Table 243. Towa Pharmaceutical Latest Developments
Table 244. Nichi-Iko Pharmaceutical Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors
Table 245. Nichi-Iko Pharmaceutical GABA Receptor Agonists Product Portfolios and Specifications
Table 246. Nichi-Iko Pharmaceutical GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026)
Table 247. Nichi-Iko Pharmaceutical Main Business
Table 248. Nichi-Iko Pharmaceutical Latest Developments
Table 249. Zhejiang Jingxin Pharmaceutical Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors
Table 250. Zhejiang Jingxin Pharmaceutical GABA Receptor Agonists Product Portfolios and Specifications
Table 251. Zhejiang Jingxin Pharmaceutical GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026)
Table 252. Zhejiang Jingxin Pharmaceutical Main Business
Table 253. Zhejiang Jingxin Pharmaceutical Latest Developments
Table 254. Jiangsu Nhwa Pharmaceutical Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors
Table 255. Jiangsu Nhwa Pharmaceutical GABA Receptor Agonists Product Portfolios and Specifications
Table 256. Jiangsu Nhwa Pharmaceutical GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026)
Table 257. Jiangsu Nhwa Pharmaceutical Main Business
Table 258. Jiangsu Nhwa Pharmaceutical Latest Developments
Table 259. Yichang Humanwell Pharmaceutical Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors
Table 260. Yichang Humanwell Pharmaceutical GABA Receptor Agonists Product Portfolios and Specifications
Table 261. Yichang Humanwell Pharmaceutical GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026)
Table 262. Yichang Humanwell Pharmaceutical Main Business
Table 263. Yichang Humanwell Pharmaceutical Latest Developments
Table 264. Shandong Sine Pharmaceutical Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors
Table 265. Shandong Sine Pharmaceutical GABA Receptor Agonists Product Portfolios and Specifications
Table 266. Shandong Sine Pharmaceutical GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026)
Table 267. Shandong Sine Pharmaceutical Main Business
Table 268. Shandong Sine Pharmaceutical Latest Developments
Table 269. Shanghai SPH Sine Pharmaceutical Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors
Table 270. Shanghai SPH Sine Pharmaceutical GABA Receptor Agonists Product Portfolios and Specifications
Table 271. Shanghai SPH Sine Pharmaceutical GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026)
Table 272. Shanghai SPH Sine Pharmaceutical Main Business
Table 273. Shanghai SPH Sine Pharmaceutical Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of GABA Receptor Agonists
Figure 2. GABA Receptor Agonists Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global GABA Receptor Agonists Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global GABA Receptor Agonists Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. GABA Receptor Agonists Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. GABA Receptor Agonists Sales Market Share by Country/Region (2025)
Figure 10. GABA Receptor Agonists Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of GABA_A receptor-targeted drugs
Figure 12. Product Picture of GABA_B receptor-targeted drugs
Figure 13. Product Picture of Others
Figure 14. Global GABA Receptor Agonists Sales Market Share by Type in 2026
Figure 15. Global GABA Receptor Agonists Revenue Market Share by Type (2021-2026)
Figure 16. Product Picture of Direct GABA receptor agonists
Figure 17. Product Picture of Positive allosteric modulators
Figure 18. Product Picture of Others
Figure 19. Global GABA Receptor Agonists Sales Market Share by Pharmacological Action Mode in 2026
Figure 20. Global GABA Receptor Agonists Revenue Market Share by Pharmacological Action Mode (2021-2026)
Figure 21. Product Picture of Oral dosage forms
Figure 22. Product Picture of Injectable dosage forms
Figure 23. Product Picture of Others
Figure 24. Global GABA Receptor Agonists Sales Market Share by Dosage Form in 2026
Figure 25. Global GABA Receptor Agonists Revenue Market Share by Dosage Form (2021-2026)
Figure 26. GABA Receptor Agonists Consumed in Attention Deficit Hyperactivity Disorder (ADHD)
Figure 27. Global GABA Receptor Agonists Market: Attention Deficit Hyperactivity Disorder (ADHD) (2021-2026) & (K Dose)
Figure 28. GABA Receptor Agonists Consumed in Psychiatric Disorders and Depression
Figure 29. Global GABA Receptor Agonists Market: Psychiatric Disorders and Depression (2021-2026) & (K Dose)
Figure 30. GABA Receptor Agonists Consumed in Alzheimer
Figure 31. Global GABA Receptor Agonists Market: Alzheimer (2021-2026) & (K Dose)
Figure 32. GABA Receptor Agonists Consumed in Epilepsy and Seizure
Figure 33. Global GABA Receptor Agonists Market: Epilepsy and Seizure (2021-2026) & (K Dose)
Figure 34. GABA Receptor Agonists Consumed in Anxiety and Sleep Disorders
Figure 35. Global GABA Receptor Agonists Market: Anxiety and Sleep Disorders (2021-2026) & (K Dose)
Figure 36. GABA Receptor Agonists Consumed in Obesity and Alcoholism
Figure 37. Global GABA Receptor Agonists Market: Obesity and Alcoholism (2021-2026) & (K Dose)
Figure 38. Global GABA Receptor Agonists Sale Market Share by Application (2025)
Figure 39. Global GABA Receptor Agonists Revenue Market Share by Application in 2025
Figure 40. GABA Receptor Agonists Sales by Company in 2025 (K Dose)
Figure 41. Global GABA Receptor Agonists Sales Market Share by Company in 2025
Figure 42. GABA Receptor Agonists Revenue by Company in 2025 ($ millions)
Figure 43. Global GABA Receptor Agonists Revenue Market Share by Company in 2025
Figure 44. Global GABA Receptor Agonists Sales Market Share by Geographic Region (2021-2026)
Figure 45. Global GABA Receptor Agonists Revenue Market Share by Geographic Region in 2025
Figure 46. Americas GABA Receptor Agonists Sales 2021-2026 (K Dose)
Figure 47. Americas GABA Receptor Agonists Revenue 2021-2026 ($ millions)
Figure 48. APAC GABA Receptor Agonists Sales 2021-2026 (K Dose)
Figure 49. APAC GABA Receptor Agonists Revenue 2021-2026 ($ millions)
Figure 50. Europe GABA Receptor Agonists Sales 2021-2026 (K Dose)
Figure 51. Europe GABA Receptor Agonists Revenue 2021-2026 ($ millions)
Figure 52. Middle East & Africa GABA Receptor Agonists Sales 2021-2026 (K Dose)
Figure 53. Middle East & Africa GABA Receptor Agonists Revenue 2021-2026 ($ millions)
Figure 54. Americas GABA Receptor Agonists Sales Market Share by Country in 2025
Figure 55. Americas GABA Receptor Agonists Revenue Market Share by Country (2021-2026)
Figure 56. Americas GABA Receptor Agonists Sales Market Share by Type (2021-2026)
Figure 57. Americas GABA Receptor Agonists Sales Market Share by Application (2021-2026)
Figure 58. United States GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions)
Figure 59. Canada GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions)
Figure 60. Mexico GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions)
Figure 61. Brazil GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions)
Figure 62. APAC GABA Receptor Agonists Sales Market Share by Region in 2025
Figure 63. APAC GABA Receptor Agonists Revenue Market Share by Region (2021-2026)
Figure 64. APAC GABA Receptor Agonists Sales Market Share by Type (2021-2026)
Figure 65. APAC GABA Receptor Agonists Sales Market Share by Application (2021-2026)
Figure 66. China GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions)
Figure 67. Japan GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions)
Figure 68. South Korea GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions)
Figure 69. Southeast Asia GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions)
Figure 70. India GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions)
Figure 71. Australia GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions)
Figure 72. China Taiwan GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions)
Figure 73. Europe GABA Receptor Agonists Sales Market Share by Country in 2025
Figure 74. Europe GABA Receptor Agonists Revenue Market Share by Country (2021-2026)
Figure 75. Europe GABA Receptor Agonists Sales Market Share by Type (2021-2026)
Figure 76. Europe GABA Receptor Agonists Sales Market Share by Application (2021-2026)
Figure 77. Germany GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions)
Figure 78. France GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions)
Figure 79. UK GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions)
Figure 80. Italy GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions)
Figure 81. Russia GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions)
Figure 82. Middle East & Africa GABA Receptor Agonists Sales Market Share by Country (2021-2026)
Figure 83. Middle East & Africa GABA Receptor Agonists Sales Market Share by Type (2021-2026)
Figure 84. Middle East & Africa GABA Receptor Agonists Sales Market Share by Application (2021-2026)
Figure 85. Egypt GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions)
Figure 86. South Africa GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions)
Figure 87. Israel GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions)
Figure 88. Turkey GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions)
Figure 89. GCC Countries GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions)
Figure 90. Manufacturing Cost Structure Analysis of GABA Receptor Agonists in 2026
Figure 91. Manufacturing Process Analysis of GABA Receptor Agonists
Figure 92. Industry Chain Structure of GABA Receptor Agonists
Figure 93. Channels of Distribution
Figure 94. Global GABA Receptor Agonists Sales Market Forecast by Region (2027-2032)
Figure 95. Global GABA Receptor Agonists Revenue Market Share Forecast by Region (2027-2032)
Figure 96. Global GABA Receptor Agonists Sales Market Share Forecast by Type (2027-2032)
Figure 97. Global GABA Receptor Agonists Revenue Market Share Forecast by Type (2027-2032)
Figure 98. Global GABA Receptor Agonists Sales Market Share Forecast by Application (2027-2032)
Figure 99. Global GABA Receptor Agonists Revenue Market Share Forecast by Application (2027-2032)